Allogenica

Executive Summary

Allogenica is a Paris-based preclinical biotechnology company developing a next-generation off-the-shelf cell therapy platform using engineered pre-T cells derived from healthy donor stem cells. Founded in 2019, the company aims to overcome key limitations of current T-cell therapies, such as high cost, manufacturing complexity, and limited patient access, by providing universally available, safer, and more affordable treatments. Initially targeting oncology, Allogenica's platform has potential applications in rare diseases and autoimmune disorders. The platform's off-the-shelf nature and use of pre-T cells could enable scalable production and reduce the risk of graft-versus-host disease, positioning it as a promising candidate in the rapidly growing cell therapy market. While still in preclinical stages, Allogenica's innovative approach addresses significant unmet needs and could capture substantial value if successfully translated into clinical candidates.

Upcoming Catalysts (preview)

• Q4 2025Preclinical Proof-of-Concept Data for Lead Program60% success
• Q1 2026Series A or Series B Financing Announcement70% success
• Q2 2026Strategic Partnership or Licensing Deal with Larger Pharma40% success